$1 Million Granted to Investigate Cardiovascular Benefits of GLP-1 Therapy
In recent years, glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists, collectively known as GLP-1/GIP agonists, have emerged as groundbreaking therapies initially designed to manage...
















